thalidomide has been researched along with Multiple Sclerosis in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Contino-Pépin, C | 3 |
| Parat, A | 2 |
| Périno, S | 1 |
| Lenoir, C | 1 |
| Vidal, M | 1 |
| Galons, H | 1 |
| Karlik, S | 1 |
| Pucci, B | 2 |
| Patinote, C | 2 |
| Roscoe, WA | 2 |
| Karlik, SJ | 2 |
| Owens, T | 1 |
| Sastry, PS | 1 |
2 reviews available for thalidomide and Multiple Sclerosis
| Article | Year |
|---|---|
Targeting vascular changes in lesions in multiple sclerosis and experimental autoimmune encephalomyelitis.
Topics: Angiogenesis Inhibitors; Animals; Drug Delivery Systems; Encephalomyelitis, Autoimmune, Experimental | 2012 |
Identification of new therapeutic targets for prevention of CNS inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antigens, CD; B7-2 Antigen; Cytokines; En | 2002 |
3 other studies available for thalidomide and Multiple Sclerosis
| Article | Year |
|---|---|
Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Cell Proliferation; Chemistry, Pharmaceutical; Drug Des | 2009 |
Thalidomide derivatives for the treatment of neuroinflammation.
Topics: Administration, Oral; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; | 2010 |
Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis.
Topics: Disease Progression; Humans; Models, Neurological; Multiple Sclerosis; Thalidomide; Tumor Necrosis F | 1999 |